Master data| INID | Criterion | Field | Content |
|---|
| Type of IP right | SART | Patent |
| Status | ST | Not pending/lapsed |
| 21 | DE file number | DAKZ | 689 29 563.4 |
| 96 | EP file number | EAKZ | 02 00 9255.7 |
| 97 | EP publication number | EPN | 1225168 |
| 54 | Designation/title | TI | Prostaglandin-F-2-alpha Derivat zur Behandlung von Glaukom und Augenhochdruck |
| 51 | IPC main class | ICM
(ICMV) | C07C 405/00 (2006.01) |
| 51 | IPC secondary class(es) | ICS
(ICSV) | A61K 31/557 (2006.01), A61P 27/02 (2006.01) |
| 22 | DE application date | DAT | Sep 6, 1989 |
| 96 | EP application date | EAT | Sep 6, 1989 |
| 43 | Date of first publication | OT | Jul 24, 2002 |
| Date of publication of grant | PET | Jan 14, 2009 |
| 71/73 | Applicant/owner | INH | Pfizer Health AB, Stockholm, SE |
| 72 | Inventor | IN | Stjernschantz, Johan W., 752 38 Uppsala, SE; Resul, Bahram, 754 49 Uppsala, SE |
| Address for service | | Pfizer Ltd. European Pharma Patent Department, SANDWICH, KENT CT13 9NJ, GB |
33
31
32
| Foreign priority | PRC
PRNA
PRDA
| SE
8803855
Oct 28, 1988
|
33
31
32
| Foreign priority | PRC
PRNA
PRDA
| SE
8803110
Sep 6, 1988
|
| Patent division in charge | | 44 |
| 97 | EP language of publication | ELANG | EN - Englisch |
| 84 | Designated EP contracting states | EDS | AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE |
| Published EP/WO documents | EPWOPN | Original document:
EP000001225168
Searchable text:
EP000001225168
Original document:
EP000001225168B1
Searchable text:
EP000001225168B1 |
| 43 | Date of first publication | EVT | Jul 24, 2002 |
| Date of the first transfer into DPMAregister | EREGT | Sep 29, 2012 |
| Date of the (most recent) update in DPMAregister | REGT | Apr 30, 2022
(Show all update days)(Hide all update days)- Apr 30, 2022; Feb 26, 2015; Jan 22, 2015; Jan 9, 2014; Oct 16, 2013; Oct 15, 2013; Jan 23, 2013
- Historical data not available for this/these date(s)
- Sep 29, 2012
- Date of the first transfer into DPMAregister
|
